Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Illinois Joins WHO Global Outbreak Network After U.S. Exit, Following California’s Lead 
Ohio Man Indicted for Alleged Threat Against Vice President JD Vance, Faces Additional Federal Charges 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants 
U.S. Sanctions on Russia Could Expand as Ukraine Peace Talks Continue, Says Treasury Secretary Bessent 
UAE Plans Temporary Housing Complex for Displaced Palestinians in Southern Gaza 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Trump Says “Very Good Talks” Underway on Russia-Ukraine War as Peace Efforts Continue 
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns 
Australia’s December Trade Surplus Expands but Falls Short of Expectations 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure 
Trump Orders DHS to Avoid Protests in Democratic Cities Unless Federal Assets Are Threatened 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
U.S. President Donald Trump announced sweeping new trade tariffs Thursday evening, including a 100% levy on imported pharmaceutical products, marking one of his most aggressive moves to date in reshaping America’s trade policy. The new tariffs, set to take effect October 1, will also include a 25% duty on heavy truck imports, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture.
According to Trump, the pharmaceutical tariffs will apply to all branded or patented products, though companies actively building manufacturing plants in the United States will be exempt. He specified that firms must have already broken ground or begun construction on U.S. facilities to qualify. Trump framed the move as a matter of national security and a necessary step to reduce dependency on foreign drug imports.
The United States imported over $212 billion worth of pharmaceutical products in 2024, government data shows. Trump has long criticized this reliance, arguing that it threatens U.S. security and weakens domestic industries. Earlier this year, he demanded that 17 major drugmakers lower domestic drug prices while raising them abroad to balance profits. In August, Trump warned he could hike tariffs as high as 250%, signaling the seriousness of his push for reshoring production.
The tariff threats have already spurred huge investment pledges from global pharma companies. Roche committed to investing $50 billion, while Novartis announced $23 billion in U.S. facilities. American firms including Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are also ramping up domestic operations to hedge against the new trade policies.
These tariffs extend beyond pharmaceuticals, targeting industries like heavy trucks, fittings, and furniture—sectors Trump says need protection to revive U.S. manufacturing and safeguard jobs. While the full impact of these measures on trade partners remains unclear, they underscore the administration’s continued reliance on tariffs as a core tool in its economic agenda.
